Silibin (Silybin)

Silybin (also spelled silibinin) is the primary bioactive flavonolignan derived from milk thistle (Silybum marianum) seed extract, accounting for roughly 50–60% of the silymarin complex. It exerts hepatoprotective and antioxidant effects primarily by scavenging reactive oxygen species, inhibiting NF-κB signaling, and stabilizing hepatocyte membrane permeability.

Origin & History

Silybin, also known as silibinin, is a polyphenolic flavonolignan that serves as the primary active compound in silymarin, an extract from the seeds of the milk thistle plant (*Silybum marianum*). It constitutes 50-70% of the extract and is typically isolated as an equimolar mixture of its two diastereomers, silybin A and silybin B, through processes like silica gel chromatography and recrystallization.

Historical & Cultural Context

The provided research dossier contains no information regarding the historical or traditional use of silybin. Its context is presented solely as a modern, isolated constituent of silymarin from milk thistle.

Health Benefits

[{"benefit": "Exhibits direct antioxidant activity by scavenging superoxide anion radicals and nitric oxide.", "evidence_quality": "Evidence is preliminary, based on in-vitro/cellular mechanism studies [1]."}, {"benefit": "Helps preserve the body's own antioxidant enzymes, including superoxide dismutase, catalase, and glutathione peroxidase.", "evidence_quality": "Evidence is preliminary, based on in-vitro/cellular mechanism studies [1]."}, {"benefit": "May reduce markers of cellular damage by decreasing malondialdehyde levels.", "evidence_quality": "Evidence is preliminary, based on in-vitro/cellular mechanism studies [1]."}, {"benefit": "Functions as an iron chelator, a mechanism observed in cellular models.", "evidence_quality": "Evidence is preliminary, based on in-vitro/cellular mechanism studies [1]."}, {"benefit": "Interacts with bile acid transporters, suggesting a role in influencing organic anion exchange within the body.", "evidence_quality": "Evidence is preliminary, based on in-vitro/cellular mechanism studies [2]."}]

How It Works

Silybin directly scavenges superoxide anion radicals (O₂⁻) and nitric oxide (NO) while upregulating endogenous antioxidant enzymes superoxide dismutase (SOD), catalase, and glutathione peroxidase. It inhibits NF-κB nuclear translocation, thereby suppressing pro-inflammatory cytokines TNF-α and IL-6, and also blocks the enzyme RNA polymerase I in hepatocytes, reducing protein synthesis in activated stellate cells to slow fibrosis. Additionally, silybin modulates the PI3K/Akt and MAPK signaling cascades, influencing hepatocyte survival and apoptosis pathways.

Scientific Research

The provided research dossier lacks specific details on human clinical trials, randomized controlled trials, or meta-analyses for silybin. No PubMed PMIDs, study designs, sample sizes, or specific clinical outcomes were available in the source materials.

Clinical Summary

Human clinical data for silybin specifically (versus the broader silymarin complex) remains limited and mostly early-phase. A randomized controlled trial in 72 patients with non-alcoholic fatty liver disease (NAFLD) using a silybin-phosphatidylcholine-vitamin E complex (Realsil) over 12 months showed significant reductions in ALT, AST, and liver fibrosis markers compared to placebo. A separate study in 138 hepatitis C patients found oral silybin infusion reduced viral load, though effects were not sustained post-treatment. Overall, evidence is predominantly from in vitro studies, animal models, and small-to-moderate human trials, making definitive efficacy conclusions premature.

Nutritional Profile

Silibinin (Silybin) is a purified flavonolignan compound, not a whole food ingredient, and therefore has no meaningful macronutrient, vitamin, or mineral profile in the traditional nutritional sense. It is a single bioactive molecule with a molecular weight of 482.44 g/mol (C25H22O10). As a compound, it contains no protein, fat, carbohydrates, fiber, vitamins, or dietary minerals. It is the primary active constituent of silymarin, the standardized extract of milk thistle (Silybum marianum) seeds, comprising approximately 50–70% of silymarin by weight. Silibinin itself exists as a diastereomeric pair: Silybin A and Silybin B, typically in roughly equal proportions. Bioavailability of free silibinin is notably poor due to low aqueous solubility and limited intestinal absorption, with oral bioavailability estimated at less than 1–5% for the unconjugated form. Phospholipid complexes (e.g., Silybin-Phosphatidylcholine, trade name Siliphos) have been shown to improve bioavailability by approximately 4–10 fold compared to unformulated silibinin. Peak plasma concentrations (Cmax) following a standard 140 mg oral dose of silymarin are typically in the nanomolar to low micromolar range for silibinin. It undergoes extensive phase II conjugation (glucuronidation and sulfation) in the intestine and liver, with conjugated metabolites being the predominant circulating forms. Half-life is approximately 6 hours. No caloric value is applicable.

Preparation & Dosage

The research dossier does not specify any clinically studied dosage ranges for silybin in its various forms. Standardization details from clinical studies are not provided. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Information on ingredients that work synergistically with silybin is not available in the provided research dossier.

Safety & Interactions

Silybin is generally well tolerated; the most commonly reported side effects are mild gastrointestinal symptoms including nausea, diarrhea, and bloating, particularly at higher doses exceeding 400 mg/day. It inhibits cytochrome P450 enzymes CYP3A4, CYP2C9, and CYP2D6, creating clinically relevant interactions with immunosuppressants (cyclosporine, tacrolimus), anticoagulants (warfarin), and certain statins. Silybin may enhance the hepatotoxic clearance of drugs metabolized by these enzymes and has demonstrated additive effects with some chemotherapy agents, requiring oncology supervision. Safety data in pregnancy and lactation is insufficient, so use is not recommended in these populations without physician guidance.